10x Genomics Inc. Insider Trading

TXG

Last 12 months

Insiders sold $16.9M and bought nothing on the open market.

57% of the selling was scheduled in advance under 10b5-1 plans. Director John R Stuelpnagel sold $1.24M on Sep 3, 5.7% of their stake, outside a plan. The last open-market buy by an executive or director was in Feb 2025.

Net open-market

−$16.9M

0 buys · 26 sales

Under a 10b5-1 plan

57%

of the value sold

Insiders who bought / sold

0 / 6

executives and directors

Last open-market buy

Feb 2025

Feb 21, 2025

Get an email when TXG's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Sep 22	Shehnaaz Suliman Director	Sold10b5-1 plan 5 parts	5,723	$81.19 average	465K	19%	Form 4
Sep 22	Serge Saxonov Chief Executive Officer	Sold10b5-1 plan 5 parts	25,000	$81.22 average	$2.03M	2.3%	Form 4
Sep 9	Adam Taich Chief Financial Officer	Sold10b5-1 plan 3 parts	46,388	$64.58 average	$3M	13%	Form 4
Sep 3	John R Stuelpnagel Director	SoldNo plan 3 parts	20,000	$61.76 average	$1.24M	5.7%	Form 4
Aug 26	Serge Saxonov Chief Executive Officer	Sold10b5-1 plan 3 parts	10,486	$63.70 average	668K	0.9%	Form 4
Aug 24	Serge Saxonov Chief Executive Officer	SoldNo plan	18,545	$63.02	$1.17M	1.6%	Form 4
Aug 24	Adam Taich Chief Financial Officer	SoldNo plan	17,166	$63.02	$1.08M	4.5%	Form 4
Aug 24	Benjamin J. Hindson See Remarks	SoldNo plan	13,818	$63.02	871K	2.8%	Form 4
Aug 24	Shehnaaz Suliman Director	Sold10b5-1 plan 2 parts	2,207	$63.65 average	140K	7.0%	Form 4
Aug 13 – 14	Sarah A. Teichmann Director	Sold10b5-1 plan 2 parts	7,551	$57.25 average	432K	21%	Form 4
Aug 11	John R Stuelpnagel Director	SoldNo plan 2 parts	20,000	$57.75 average	$1.16M	5.4%	Form 4
Jun 22	Serge Saxonov Chief Executive Officer	Sold10b5-1 plan 4 parts	30,000	$34.44 average	$1.03M	2.5%	Form 4
Jun 16	Shehnaaz Suliman Director	Sold10b5-1 plan 2 parts	5,723	$32.63 average	187K	15%	Form 4
May 22 – 26	Serge Saxonov Chief Executive Officer	Sold10b5-1 plan 2 parts	28,893	$24.54 average	709K	2.5%	Form 4
May 22	Benjamin J. Hindson See Remarks	SoldNo plan	11,595	$24.44	283K	2.3%	Form 4
May 22	Adam Taich Chief Financial Officer	SoldNo plan	15,098	$24.44	369K	3.8%	Form 4
Apr 14	Serge Saxonov Chief Executive Officer	Sold10b5-1 plan	5,000	$24.56	123K	0.4%	Form 4
Mar 23 – 24	Serge Saxonov Chief Executive Officer	Sold10b5-1 plan 2 parts	15,000	$19.26 average	289K	1.1%	Form 4
Mar 2	Serge Saxonov Chief Executive Officer	Sold10b5-1 plan 2 parts	16,152	$22.73 average	367K	1.3%	Form 4
Feb 25	Sarah A. Teichmann Director	Sold10b5-1 plan	7,579	$19.41	147K	22%	Form 4
Feb 23	Serge Saxonov Chief Executive Officer	SoldNo plan	9,632	$18.58	179K	0.9%	Form 4
Feb 23	Adam Taich Chief Financial Officer	SoldNo plan	8,968	$18.58	167K	3.0%	Form 4
Feb 23	Benjamin J. Hindson See Remarks	SoldNo plan	7,826	$18.58	145K	1.8%	Form 4
Nov 24, 2025	Adam Taich Chief Financial Officer	SoldNo plan	11,888	$19.00	226K	3.8%	Form 4
Nov 24, 2025	Benjamin J. Hindson See Remarks	SoldNo plan	8,283	$19.00	157K	1.9%	Form 4
Nov 24, 2025	Serge Saxonov Chief Executive Officer	SoldNo plan	13,261	$19.00	252K	1.3%	Form 4
Aug 22, 2025	Serge Saxonov Chief Executive Officer	SoldNo plan	9,348	$13.79	129K	1.0%	Form 4
Aug 22, 2025	Adam Taich Chief Financial Officer	SoldNo plan	22,315	$13.79	308K	6.7%	Form 4
Aug 22, 2025	Benjamin J. Hindson See Remarks	SoldNo plan	7,486	$13.79	103K	1.7%	Form 4
May 22, 2025	Serge Saxonov Chief Executive Officer	SoldNo plan	9,343	$8.30	78K	0.8%	Form 4
May 22, 2025	Benjamin J. Hindson See Remarks	SoldNo plan	7,485	$8.30	62K	1.6%	Form 4
May 22, 2025	Adam Taich Chief Financial Officer	SoldNo plan	4,044	$8.30	34K	1.2%	Form 4
Feb 28, 2025	Serge Saxonov Chief Executive Officer	Sold10b5-1 plan	7,942	$10.63	84K	0.8%	Form 4
Feb 24, 2025	Benjamin J. Hindson See Remarks	SoldNo plan	4,573	$11.07	51K	1.3%	Form 4
Feb 24, 2025	Serge Saxonov Chief Executive Officer	SoldNo plan	5,092	$11.07	56K	0.6%	Form 4
Feb 21, 2025	Alan Mateo Director	Bought	40,000	$11.14	446K	184%	Form 4
Nov 22, 2024	Serge Saxonov Chief Executive Officer	SoldNo plan	6,693	$13.69	92K	0.7%	Form 4
Nov 22, 2024	Benjamin J. Hindson See Remarks	SoldNo plan	5,807	$13.69	79K	1.7%	Form 4

Sep 2210b5-1 plan
Shehnaaz Suliman
Director · sold 5,723 at avg $81.19
465K
19% of stake
Sep 2210b5-1 plan
Serge Saxonov
Chief Executive Officer · sold 25,000 at avg $81.22
$2.03M
2.3% of stake
Sep 910b5-1 plan
Adam Taich
Chief Financial Officer · sold 46,388 at avg $64.58
$3M
13% of stake
Sep 3No plan
John R Stuelpnagel
Director · sold 20,000 at avg $61.76
$1.24M
5.7% of stake
Aug 2610b5-1 plan
Serge Saxonov
Chief Executive Officer · sold 10,486 at avg $63.70
668K
0.9% of stake
Aug 24No plan
Serge Saxonov
Chief Executive Officer · sold 18,545 at $63.02
$1.17M
1.6% of stake
Aug 24No plan
Adam Taich
Chief Financial Officer · sold 17,166 at $63.02
$1.08M
4.5% of stake
Aug 24No plan
Benjamin J. Hindson
See Remarks · sold 13,818 at $63.02
871K
2.8% of stake
Aug 2410b5-1 plan
Shehnaaz Suliman
Director · sold 2,207 at avg $63.65
140K
7.0% of stake
Aug 13 – 1410b5-1 plan
Sarah A. Teichmann
Director · sold 7,551 at avg $57.25
432K
21% of stake
Aug 11No plan
John R Stuelpnagel
Director · sold 20,000 at avg $57.75
$1.16M
5.4% of stake
Jun 2210b5-1 plan
Serge Saxonov
Chief Executive Officer · sold 30,000 at avg $34.44
$1.03M
2.5% of stake
Jun 1610b5-1 plan
Shehnaaz Suliman
Director · sold 5,723 at avg $32.63
187K
15% of stake
May 22 – 2610b5-1 plan
Serge Saxonov
Chief Executive Officer · sold 28,893 at avg $24.54
709K
2.5% of stake
May 22No plan
Benjamin J. Hindson
See Remarks · sold 11,595 at $24.44
283K
2.3% of stake
May 22No plan
Adam Taich
Chief Financial Officer · sold 15,098 at $24.44
369K
3.8% of stake
Apr 1410b5-1 plan
Serge Saxonov
Chief Executive Officer · sold 5,000 at $24.56
123K
0.4% of stake
Mar 23 – 2410b5-1 plan
Serge Saxonov
Chief Executive Officer · sold 15,000 at avg $19.26
289K
1.1% of stake
Mar 210b5-1 plan
Serge Saxonov
Chief Executive Officer · sold 16,152 at avg $22.73
367K
1.3% of stake
Feb 2510b5-1 plan
Sarah A. Teichmann
Director · sold 7,579 at $19.41
147K
22% of stake
Feb 23No plan
Serge Saxonov
Chief Executive Officer · sold 9,632 at $18.58
179K
0.9% of stake
Feb 23No plan
Adam Taich
Chief Financial Officer · sold 8,968 at $18.58
167K
3.0% of stake
Feb 23No plan
Benjamin J. Hindson
See Remarks · sold 7,826 at $18.58
145K
1.8% of stake
Nov 24, 2025No plan
Adam Taich
Chief Financial Officer · sold 11,888 at $19.00
226K
3.8% of stake
Nov 24, 2025No plan
Benjamin J. Hindson
See Remarks · sold 8,283 at $19.00
157K
1.9% of stake
Nov 24, 2025No plan
Serge Saxonov
Chief Executive Officer · sold 13,261 at $19.00
252K
1.3% of stake
Aug 22, 2025No plan
Serge Saxonov
Chief Executive Officer · sold 9,348 at $13.79
129K
1.0% of stake
Aug 22, 2025No plan
Adam Taich
Chief Financial Officer · sold 22,315 at $13.79
308K
6.7% of stake
Aug 22, 2025No plan
Benjamin J. Hindson
See Remarks · sold 7,486 at $13.79
103K
1.7% of stake
May 22, 2025No plan
Serge Saxonov
Chief Executive Officer · sold 9,343 at $8.30
78K
0.8% of stake
May 22, 2025No plan
Benjamin J. Hindson
See Remarks · sold 7,485 at $8.30
62K
1.6% of stake
May 22, 2025No plan
Adam Taich
Chief Financial Officer · sold 4,044 at $8.30
34K
1.2% of stake
Feb 28, 202510b5-1 plan
Serge Saxonov
Chief Executive Officer · sold 7,942 at $10.63
84K
0.8% of stake
Feb 24, 2025No plan
Benjamin J. Hindson
See Remarks · sold 4,573 at $11.07
51K
1.3% of stake
Feb 24, 2025No plan
Serge Saxonov
Chief Executive Officer · sold 5,092 at $11.07
56K
0.6% of stake
Feb 21, 2025
Alan Mateo
Director · bought 40,000 at $11.14
446K
184% of stake
Nov 22, 2024No plan
Serge Saxonov
Chief Executive Officer · sold 6,693 at $13.69
92K
0.7% of stake
Nov 22, 2024No plan
Benjamin J. Hindson
See Remarks · sold 5,807 at $13.69
79K
1.7% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch TXG, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Laboratory Analytical Instruments · Pick stocks to compare with TXG

CompareIntrinsic value

CTKBCytek Biosciences, Inc.

$5.88-1.34%50

PACBPacific Biosciences of California, Inc.

$2.55+4.51%26

QTRXQuanterix Corporation

$3.04+3.40%24

HBIOHarvard Bioscience, Inc.

$8.61-0.69%15

LABStandard Biotools Inc.

$0.62+1.38%35

BIOBio-Rad Laboratories Inc.

$379.99+1.35%48

RVTYRevvity Inc.

$159.44-2.47%20

BRKRBruker Corporation

$63.79+12.90%23

Held by ETFs

TXG is in 87 US ETFs. The largest of them, with TXG's weight in each:

Spot a number that looks wrong? Check it in TXG's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing TXG

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.